Selective Retention of Hydroxylated PCB Metabolites in Blood

Åke Bergman, Eva Klasson-Wehler, and Hiroaki Kuroki

Environmental Chemistry, Wallenberg Laboratory, Stockholm University, Stockholm, Sweden

Polychlorinated biphenyls (PCBs) are important environmental contaminants, and their toxicity to wildlife and humans is of major concern. PCBs form persistent and abundant metabolites. PCB methyl sulfones, that accumulate in biota. We now report that certain hydroxylated PCB metabolites show a strong and selective accumulation in mammalian blood. Plasma from experimentally PCB-dosed rats and blood from environmentally exposed grey seals (Halichoerus grypus) and humans were analyzed. Among all possible hydroxylated metabolites of PCB that may be formed, only a few, dominated by 4-OH-2,3,5,3',4'-pentachlorobiphenyl and 4-OH-2,3,5,6,2',4',5'-heptachlorobiphenyl, were found in the blood samples. All identified compounds have a structure with the hydroxy group in a para or meta position, with chlorine atoms on vicinal carbon atoms. The concentrations of hydroxylated PCB in the blood were almost in the same range as the most persistent PCB congeners both for seals and humans. Key words: blood analysis, environmental pollutants, hydroxylated metabolites, polychlorinated biphenyls, selective retention, xenobiotics.

Environ Health Perspect 102:464-469 (1994)

The environmental persistence of polychlorinated biphenyls (PCBs) is well known, and it has been proposed that their presence in organisms adversely affects a number of biological systems. Yet little is known about the mechanisms or the agents responsible for these effects, except for PCB congeners with dioxinlike effects that are mediated through binding to the aryl hydrocarbon hydroxylase (Ah) receptor (1–4). The initial step in the biotransformation of PCB involves cytochrome P450 (CYP1A1, 1A2, and CYP2B1/2B2)-mediated oxidation to arene oxides—intermediates with a limited half-life (5,6). Arene oxides are mainly transformed to hydroxylated aromatic compounds but also to sulfur-containing metabolites via the mercapturic acid pathway (MAP) (5,7). Halogenated aromatic compounds such as chlorinated biphenyls (CBs) may, depending on the number of halogen substituents and position of the substituents, form more than one arene oxide isomer from each compound. The metabolism of all different CBs present in the environment will thus result in the formation of a large number of hydroxylated PCB metabolites. Normally, the hydroxylated metabolites are excreted in feces and/or in urine, as such or conjugated to glucuronic acid or sulfate (8). Hydroxylated PCBs were also excreted in feces from environmentally PCB-exposed seals (9). Not all of the phenolic compounds are always excreted but may instead be retained in the body (10,11), either due to their high lipophilicity or reversible binding to proteins. Pentachlorophenol is retained in the blood of mammals and binds to a thyroxin-transporting protein, transthyretin (TTR) (11), and hydroxylated metabolites of 2,5,4′-triCB have been shown to be localized to intraluminal uterine fluid of pregnant mice (13).

Metabolism studies of individual CBs, e.g., 2,5,4′-triCB (CB-31, rat), 3,4,3′,4′-tetraCB (CB-77, rat and mouse), and 2,3,4,3′,4′-pentaCB (CB-105, mouse and mink) have shown that several isomers of hydroxylated metabolites, including dihydroxylated and dechlorinated metabolites, are formed (14–18). Metabolites of the two latter CBs, formed after a 1,2-shift of a chlorine atom, have also been identified. These metabolites were 4-OH-3,5,3′,4′-tetraCB from CB-77 (17,19) and 4-OH-2,3,5,3′,4′-pentaCB formed from CB-105 (16). In both cases, these metabolites were shown to be retained in the blood. However, CB-77 is present only in trace amounts in commercial PCBs: 0.45% in Aroclor 1242 and not detected in Aroclor 1254 (20). As this CB is rapidly metabolized to several other hydroxylated metabolites, it is doubtful if it is a quantitatively important metabolite. Other PCB congeners present in higher concentrations, such as CB-105 [3.7% in Aroclor 1254 (18)], may be toxicologically more important. There are also a number of CBs that have similar structures as CB-77 and CB-105 and therefore may be metabolized similarly. The major CBs of this type are 2,4,5,3′,4′-pentaCB (CB-118), 2,3,4,5,3′,4′-hexaCB (CB-156), and 2,3,4,2′,3′,4′-hexaCB (CB-128), which are present in Aroclor 1254 in amounts of 6.4%, 1.6%, and 2.1%, respectively (20).

This study investigated the general retention pattern of hydroxylated PCB metabolites in blood of rats at three time points after an oral dose of a commercial PCB product (Aroclor 1254). Blood samples from Baltic grey seals and human plasma samples were also analyzed for possible content of OH-CB. The present work is primarily aimed at structural identification of the hydroxylated CBs retained but includes data on the quantification of a major hydroxylated PCB metabolite in the blood. Ratios between the major OH-CB and a major CB are given.

Materials and Methods
Twelve male Sprague-Dawley rats (150–200 g) were divided into four groups. One group was kept as a control group and dosed with corn oil only. The rats in the other three groups were dosed orally with Aroclor 1254 (25 mg/kg body weight dissolved in 0.2 ml peanut oil) once a day for 3 days. The rats were kept on a 12 hr/12 hr light/dark cycle and given food and water ad libitum. The rats in one group were killed 24 hr after the last gavage; the rats in the second group were killed after 7 days, and the rats in the last group were killed after 14 days. We collected blood (plasma), lungs, livers, kidneys, and adipose tissue from all the rats and analyzed them for PCB and potential OH-CBs.

Human plasma samples (six samples) were kindly donated by Danderyds Hospital Blood Donor Centre. The samples were randomly selected and contained plasma from females (20, 20, and 42 years old) and males (23, 48, and 53 years old). The blood samples from five female grey seals, obtained as coagulates, were kindly donated by Mats Olsson, Swedish Museum of Natural History; [GS A92/5077 (124 kg), GS A92/5986 (41 kg), GS A92/5098 (44 kg), GS A91/5149 (75 kg), and GS A92/5095 (82 kg)].

Aroclor 1254, a commercial PCB product from Monsanto (Washington, DC USA), was used for the animal experiments. We synthesized 48 methoxy-chlorobiphenyls (MeO-CB) (unpublished), but the majority of MeO-CBs were prepared according to the Cadogan diaryl coupling reaction (21). A few of the MeO-CBs were synthesized via the Ullman diaryl coupling reaction (22) with subsequent chlorination of the MeO-CB product obtained in this coupling reaction (23). Previous synthesis of

Address correspondence to A. Bergman, Environmental Chemistry, Wallenberg Laboratory, Stockholm University, S-106 91 Stockholm, Sweden. H. Kuroki is currently at the Dalichi College of Pharmaceutical Sciences, 22-1 Tamagawa-cho, Minami-ku, Fukuoka 815, Japan. The skilled technical assistance of Maria Athanasiadou, Lotta Hovander, Anna Mörick, and Vlad Zoorec is gratefully acknowledged. The project was financially supported by the Swedish Environmental Protection Agency.

Received 18 August 1993; accepted 28 February 1994.
null
they do separate on the cyan-o-derivatized column also used for analyses. The major OH-CB in the rat plasma is therefore identified as 4-OH-2,3,5,3',4'-pentaCB. After comparison of the samples with the synthesized MeO-CB standards on two different GC columns, seven metabolites were identified. The structure of the identified compounds are shown in the chromatogram in Figure 1a.

The concentration of 4-OH-2,3,5,3',4'-pentaCB in plasma was 155 ng/g plasma on day 1 after exposure, and it decreased to 72 ng/g on day 7 and 71 ng/g on day 14 after exposure. The concentrations of the major CB, 2,4,5,2',4',5'-hexaCB on days 1, 7, and 14 were 23, 7, and 9 ng/g, respectively. This gives 4-OH-pentaCB/CB-153 ratios of 6.7, 10, and 8 for days 1, 7, and 14, respectively. The concentrations are given on a fresh weight basis because the low lipoid content in plasma makes lipid weight determination less accurate.

In Table 2, the concentrations of 4-OH-2,3,5,3',4'-pentaCB and CB-153 in the tissues are given, together with the ratio of OH-pentaCB/CB-153. Hydroxylated PCB metabolites were also determined in rat tissues (liver, lung, and kidney). The chromatographic (GC-ECD) pattern was similar to the pattern in plasma. The concentrations of the major compound, 4-OH-2,3,5,3',4'-pentaCB, were generally lower in these tissues than the concentration of CB-153 (Table 2). The ratio between the major OH-CB and CB-153 increased with time and on day 14 was about 1 in both liver and lung. No hydroxylated PCB metabolites were detected in rat adipose tissue.

The blood coagulates from five female grey seals all contained hydroxylated PCB metabolites with a similar gas chromatographic peak pattern. At least 13 OH-CBs were indicated by GC/MS (NICI), and 9 of those were identified by comparison with the authentic reference compounds. The gas chromatogram of the OH-CB fraction isolated from seal blood is shown, after methylation, in Figure 1b. The structures of the identified MeO-CBs have been inserted in the chromatogram. By using the cyan-o-derivatized GC column, the major peak in the chromatogram (Fig. 1b) was shown to consist of two compounds, 4-MeO-2,3,5,3',4'-pentaCB and 4-MeO-3,5,2',4',5'-pentaCB, in a ratio of 6:5:1. An unidentified MeO-hexaCB was among the three second-most abundant compounds. The structures of two other abundant metabolites were assigned as 4-MeO-3,5,2',4',5'-pentaCB and 3-MeO-2,4,5,2',3',4',5'-heptaCB according to similar GC and GC/MS properties as the authentic standards. Two MeO-CBs, 4-MeO-2,3,5,

| Tissue                  | CB-153 | 4-OH-pentaCB | 4-OH-pentaCB/CB-153 |
|-------------------------|--------|--------------|---------------------|
| Lung, day 1             | 19     | 0.9          | 0.05                |
| Lung, day 7             | 6.6    | 2.0          | 0.3                 |
| Lung, day 14            | 2.4    | 1.8          | 0.8                 |
| Liver, day 1            | 6.8    | 0.7          | 0.1                 |
| Liver, day 7            | 1.7    | 1.8          | 1.1                 |
| Liver, day 14           | 1.0    | 1.0          | —                   |
| Kidney, day 1           | NA     | NA           | —                   |
| Kidney, day 7           | 4.0    | 0.9          | 0.2                 |
| Kidney, day 14          | 3.1    | 0.1          | 0.03                |
| Adipose tissue, day 1   | 1.9    | ND           | 0                   |
| Adipose tissue, day 7   | 3.5    | ND           | 0                   |
| Adipose tissue, day 14  | 1.2    | ND           | 0                   |

Abbreviations: CB, chlorinated biphenyl; NA, not analyzed; ND, not detectable.

Discussion

In the present study, a crucial first experiment was performed by gavage treatment of rats with a technical PCB product and subsequent analysis of PCB and OH-CBs in their blood plasma. Only 13 OH-CBs were present in the rat plasma, a significantly lower number than expected, as many of the individual CBs in the PCB product may be transformed to several different hydroxylated metabolites. The estimated number of potential OH-CB metabolites formed from PCB may be as many as 200 individual compounds. No OH-CBs were detected in adipose tissue at any survival time, although they were present in the other tissues analyzed. Their presence in these tissues may partially be explained by blood residues in the tissues. It is striking that the concentration of the hydroxylated metabolite of CB-105, for example, is higher than one of the most persistent PCB congeners, CB-153. Taken together, these results strongly indicate a specific mechanism for the retention of OH-CBs in the rat plasma. This hypothesis is further strengthened by the fact that the retained OH-CBs have some basic structural similarities. The OH-group is substituted in the 4-position of most OH-CBs identified but may also be substituted in the 3-position in one of the phenyl rings. In all identified OH-CBs, there are chlo-
Figure 1. Gas chromatograms of hydroxylated chlorinated biphenyls (OH-CBs), after methylation and GC separation on a DB-5 fused silica capillary column of (a) plasma from rats 1 day after oral doses of a commercial PCB, Aroclor 1254. Structures of identified methoxy chlorinated biphenyls (MeO-CBs) are shown or number of chlorine atoms in the MeO-CBs are given above the peaks in case the structure has not been identified. (b) Chromatogram of methylated OH-CBs in grey seal blood. (c) Chromatogram of methylated OH-CBs in human plasma.
lire atoms on the adjacent carbons to the OH-group, and all OH-CBs are substituted with five or more chlorine atoms.

In most cases the parent CBs can be traced from the identified OH-CBs and the general known pathways for PCB metabolism. Thus, the OH-CBs identified in rat plasma are most likely metabolites of 2,4,5,3',4'-pentaCB (CB-118), 2,3,4,3',4'-pentaCB (CB-105), 2,3,4,2',4',5'-hexaCB (CB-138), 2,3,4,2',3',4'-hexaCB (CB-128), 2,3,4,5,3',4'-hexaCB (CB-156), and 2,3,4,5,2',3',4'-heptaCB (CB-170).

Because of the strong and specific retention of OH-CBs in the plasma from rats dosed with PCB (Aroclor 1254), we considered the possibility that OH-CBs might also be detected in environmental samples. Grey seals from the Baltic are known to have high levels of PCB in their blubber (28), and seals were therefore chosen for blood analysis. It was not possible to obtain fresh blood samples from any seals, but blood coagulates were collected from dead grey seals during autopsy. It is thus not possible to report the OH-CBs concentrations in plasma, so the concentrations are given on a lipid-weight basis in whole blood instead.

The grey seal blood also contained only a limited number of OH-CBs. Several of the methylated derivatives show similar retention times as the methylated OH-CBs identified in rat serum. Thus, the major peak in the chromatogram has the same retention time as 4-MeO-2,3,5,3',4'-pentaCB, but this peak also contains a minor amount of an isomeric compound, 4-MeO-3,5,2',3',4'-pentaCB. The ratio between these two CB-105 metabolites and CB-153 is 0.1:1.7, indicating similar concentrations of these metabolites as one of the most persistent PCB congeners.

The metabolites identified in the seal blood are most probably formed from CB-118; CB-105; 2,3,5,6,2',4',5'-heptaCB (CB-187); 2,3,4,6,2',3',4'-heptaCB (CB-171) or 2,3,4,6,2',4',5'-heptaCB (CB-183); CB-156; 2,3,4,5,2',4',5'-heptaCB (CB-180) and CB-170.

Human plasma, the other environmental sample analyzed for OH-CBs, also contained an appreciable concentration of these metabolites. Although several of the OH-CBs identified in the rat plasma and seal blood are present, the spectrum of OH-CBs is different in human plasma compared to these other two matrices. It is notable that the major OH-CB in human plasma is 4-OH-2,3,5,6,2',4',5'-heptaCB, a metabolite present in seal blood but not detected in the rat plasma. This major metabolite may originate from 2,3,5,6,2',4',5'-heptaCB (CB-187) and/or 2,3,4,6,2',4',5'-heptaCB (CB-183). Both these CBs are present in humans (e.g., in human milk).
at approximately the same concentrations, and it is thus not possible to further specify the parent compound(s) (29).

It is notable that the major metabolite in rat plasma and a dominating OH-CB in both seal blood and human plasma is a compound that to a major extent is formed after a 1.2-fold of a chlorine in the para position in the 2,3,4-trichlorinated phenyl ring. A similar rearrangement is also observed to occur in the 3,4-dichloro-substituted phenyl rings of CB-77, CB-105, CB-118, CB-156 (18,19). Thus, all the major 1-ortho-CBs can be transformed to 4-OH-CB metabolites that are retained in plasma or blood (Fig. 1).

A considerable variation in the relative amounts of the different OH-CBs is observed in the different species. In the rat, 4-OH-2,3,5,3',4'-pentaCB dominates, whereas the higher chlorinated OH-CBs are only minor components. In the human plasma, the hepta- and hexachlorinated OH-CBs are much more abundant compared to the rat. The seal pattern shows some similarities with both human and rat. The reason for these dissimilarities may be due to different exposure situations. The rats were given a high dose 3 days in a row, whereas humans are exposed to a low dose of PCB during a life span. The higher chlorinated PCBs are often slowly metabolized [e.g., CB-153 (30)] and may therefore not have been formed in detectable amounts in the rat under the experimental conditions used.

A possible explanation for the highly selective retention of the OH-CBs in the blood samples may be their structural resemblance with thyroxin. In a previous study on the metabolism of CB-77, blood was shown to contain 4-OH-3,5,3',4'-tetracb in a concentration 15 times higher than the parent compound, 5 days after oral exposure in mice (19). This metabolite was bound to a thyroxin-transporting protein (transthyretin) in the blood (19,31,32). Another PCB congener, 2,3,4,3',4'-pentaCB, has also been shown to be metabolized to a hydroxylated metabolite, 4-OH-2,3,5,3',4'-pentaCB, which was retained in blood after oral dose to mice (18). This metabolite is quantitatively the most important OH-CB identified in the blood samples of rats and seals in the present study.

In vitro binding studies between synthetic OH-CBs and TTR have shown that, for example, 4-OH-3,5,3',4'-pentaCB competes for the thyroxin (T₄) binding site six times more efficiently than T₄, the endogenous ligand, and twice as well as 4-OH-3,5,3',4'-tetracb (33,34). 4-OH-2,3,5,3',4'-pentaCB has not yet been tested for its binding capacity to TTR. The competitive binding of OH-CB congeners relative to T₄ has been reported also by Rickenbacher et al. (35). In that study, computer modeling showed that OH-CBs with the substituents in meta or para positions were much more effective competitors for T₄ than if the substituents were bound in an ortho position. Differences in the results from in vitro and in vivo binding studies have been observed (18,19,33,34) that indicate a more complex situation for binding than currently can be described by modeling or by in vitro studies. Thus, 4-OH-2,3,5-trichloro- or 4-OH-3,5-dichloro-substituted OH-CBs compete with T₄ both in vivo and in vitro, whereas 5-OH-3,4-dichloro-substituted OH-CBs have only been observed to compete in vitro.

The presence of selected OH-CBs in high concentrations in the blood of humans and seals gives cause for concern. PCB has been reported to inhibit the transport of thyroid hormones in rat plasma by competing with T₄ for the binding site on the thyroxin-transporting protein TTR (31,32,36). Subchronic exposure to low doses of technical-grade PCB was reported to cause reproductive and thyroid effects (37). PCB congeners have also been shown to interfere with hepatic and brain thyroid hormone metabolism in fetal and neonatal rats after subchronic exposure in utero (38). Perinatal exposure to specific PCB congeners (CB-118 and CB-153) markedly decreased serum T₄ in pups but not in dams, whereas 2,4',4'-trichloro did not show such effects (39). The two former CBs are both transformed to hydroxylated metabolites present in blood, whereas CB-28 is not likely to form metabolites that fulfill the structural requirements.

PCB has also been reported to have antiestrogenic effects (40), but in another report both antiestrogenic and estrogenic effects were claimed (41). Korach et al. (42) showed that ortho-substituted PCB congeners had a higher affinity for the estrogen receptor than CBs without ortho-chlorine atoms. In the same report, it was also shown that a 4-OH-2',4',4'-trichloro had affinity for the estrogen receptor (42). The OH-CBs identified in the present study must be further investigated in regard to their potential estrogenic activities.

The importance of the retention of a few OH-CBs in blood at levels similar to the persistent PCB congeners has hitherto been unknown, but the toxicological implications must be clarified. Studies on the toxicity of the major OH-CBs in blood must be initiated. Also, further development of the analytical methods to improve quantification of MeO-CBs must be carried out.

REFERENCES

1. Poland A, Glover E, Kende AS. Stereospecific, high affinity binding of 2,3,7,8-,tetrachlorodibenz-p-dioxin by hepatic cytosol. J Biol Chem 251:4936-4946 (1976).
2. Poland A, Knutson JC. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu Rev Pharmacol Toxicol 22:517-554 (1982).
3. Safe S, Bandiera S, Sawyer T, Zmdzka B, Mason G, Romkes M, Denomme MA, Sparling J, Okey AB, Fujita T. Environ. Effects of structure on binding to the 2,3,7,8-TCDD receptor protein and AHH induction—halogenated biphenyls. Environ Health Perspect 61:21-33 (1985).
4. Gillner M, Bergman J, Cambillau C, Fernström B, Gustafsson JÄ. Interactions of indoles with specific binding sites for 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. Mol Pharmcol 28:357-363 (1985).
5. Matthews HB. Aryl halides. In: Metabolic basis of detoxification. Metabolism of functional groups (Jakoby WB, Bend JR Caldwell J, eds). New York:Academic Press, 1982:51-55.
6. Preston BD, Miller JA, Miller EC. Reactions of 2',5',5'-tetrachlorobiphenyl-3,4-oxide with methionine, cysteine and glutathione in relation to the formation of methylthio-metabolites of 2,2',5,5'-tetrachlorobiphenyl in the rat and mouse. Chem-Biol Interact 50:289 (1984).
7. Bakke JE. Metabolites derived from glutathione conjugation. In: Intermediary xenobiotic metabolism in animals (Hotson DH, Caldwell J, Paulson GD, eds), London:Taylor and Francis, 1989;205-224.
8. Caldwell J. Conjugation mechanisms of xenobiotic metabolism: mammalian aspects. In: Xenobiotic conjugation chemistry (Paulson GD, Caldwell J, Hotson DH, Menn JJ, eds), ACS Symposium Series 299, Washington, DC:American Chemical Society, 1986:2-28.
9. Janson B, Jensen S, Olsson M, Renberg G, Sundström G, Vaz R. Identification by GC-MS of phenolic metabolites of PCB and p,p'-DDE isolated from Baltic guillemot and seal. Ambio 4:93-97 (1975).
10. Wild SR, Jones KC. Pentachlorophenol in the UK environment—I. Human exposure and an assessment of pathways. Chemosphere 24:847-856 (1992).
11. van den Berg KJ, Raaaij AGM, Bragt PC, Notten WR. Interactions of halogenated industrial chemicals with transthyretin and effects on thyroid hormone levels in vivo. Arch Toxicol 65:15-19 (1991).
12. Balschmiter KH, Mennel A, Buyten J. Long chain alkyl-polysiloxanes as non-polar stationary phases in capillary gas chromatography. Fres J Anal Chem 346:396-402 (1992).
13. Brandt I, Darnerud PO, Bergman Å, Larsson Y. Metabolism of 2,4,5-3-trichlorobiphenyl: enrichment of hydroxylated and methyl sulphone metabolites in the uterine luminal fluid of pregnant mice. Chem-Biol Interact 40:45-56 (1982).
14. Bakke JE, Fei VJ, Bergman Å. Metabolism of 2,4,5-trichlorobiphenyl in rats. Xenobiotica 13:555-564 (1983).
15. Klasson Wehler E, Bergman Å, Darnerud PO, Wachtmeister CA, 3,3',4',4'-Tetrachlorobiphenyl: excretion and tissue retention of hydroxylated metabolites in the mouse. Drug Metab Dispos 17:441-448 (1989).
16. Yoshimura H, Yonemoto Y, Yamada H, Koga N, Oguri K, Saeki S. Metabolism in vivo of 3,3',4,4'-tetrachlorobiphenyl and toxicological assessments of the metabolites in rats. Xenobiotica 17:897–910 (1987).

17. Koga N, Beppu M, Ishida C, Yoshimura H. Further studies on metabolism in vivo of 3,4,3',4'-tetrachlorobiphenyl in rats: identification of minor metabolites in rat faeces. Xenobiotica 19:1307–1318 (1989).

18. Klasson Wehler E, Lindberg L, Jönsson C-J, Bergman A. Tissue retention and metabolism of 2,3,4,3',4'-pentachlorobiphenyl. Chemosphere 27:2397–2412 (1993).

19. Klasson Wehler E. Synthesis of some radiolabelled organochlorines and metabolism studies in vivo of two PCBs (thesis). Stockholm: Stockholm University, 1989.

20. Schultz DE, Petrick G, Duincker DE. Complete characterization of polychlorinated biphenyl congeners in commercial Aroclor and Clophen mixtures by multidimensional gas chromatography electron capture detection. Environ Sci Technol 23:852–859 (1989).

21. Cadogan JIG. A convenient new method of aromatic ayalation. J Chem Soc 4257 (1962).

22. Forrest J. The Ullman biaryl synthesis. Part I. Atypical products of synthesis of 2,4-dinitrobiphenyl and related compounds. J Chem Soc 566–573 (1960).

23. Sundström G, Wachtmeister CA. Polychlorinated biphenyls III. Synthesis of two 14C-labeled hexachlorobiphenyls. Acta Chem Scand 26:3816–3818 (1972).

24. Janson B, Sundström G. Mass spectrometry of the methyl ethers of isomeric hydroxybiphenyls — potential metabolites of chlorobiphenyls. Biomed Mass Spectrom 1:386–392 (1974).

25. Sundström G. Polychlorinated biphenyls II. Synthesis of some tetra- and pentachlorobiphenyls. Acta Chem Scand 27:600–604 (1973).

26. Fieser LF, Fieser M. In: Reagents for organic synthesis, vol 1. New York: John Wiley and Sons, 1967:191–192.

27. Bergman A, Athanasiadou M, Bergek S, Haraguchi K, Jensen S, Klasson E, Klasson Wehler E. PCB and PCB methyl sulphones in milk treated with PCB and various PCB fractions. Ambio 21:570–576 (1992).

28. Haraguchi K, Athanasiadou M, Bergman A, Hovander L, Jensen S. PCB and PCB methyl sulphones in selected groups of seals from the Swedish coastwaters. Ambio 21:546–549 (1992).

29. Safe S, Safe L, Mullin M. Polychlorinated biphenyls: Congenere-specific analysis of a commercial mixture and a human milk extract. J Agric Food Chem 33:24–29 (1985).

30. Jensen S, Sundström G. Metabolic hydroxylation of a chlorobiphenyl containing only isolated unsubstituted positions—2,2',4,4',5,5'-hexachlorobiphenyl. Nature 251:219–220 (1974).

31. Brouwer A, van den Berg KJ. Binding of a metabolite of 3,3',4,4'-tetrachlorobiphenyl to transthyretin reduces serum vitamin A transport by inhibiting the formation of the protein complex carrying both retinol and thyroxin. Toxicol Appl Pharmacol 85:301–312 (1986).

32. Brouwer A, Blaser WS, Kukler A, van den Berg KJ. Study on the mechanism of interference of 3,4,3',4'-tetrachlorobiphenyl with the plasma retinol-binding proteins in rodents. Chem-Biol Interact 68:203–217 (1988).

33. Brouwer A, Klasson Wehler E, Bokdam M, Morse D, Traag W. Competitive inhibition of thyroxin binding to transthyretin by mono- and dihydroxy metabolites of 3,4,3',4'-tetrachlorobiphenyl. Chemosphere 20:1257–1262 (1990).

34. Lans MC, Klasson Wehler E, Willemsen M, Meussen E, Safe S, Brouwer A. Structure-dependent, competitive interaction of hydroxy-polychlorobiphenyls, -dibenzo-p-dioxins and -dibenzoofurans with human transthyretin. Chem-Biol Interact 88:7–21 (1993).

35. Rickenbacher U, McKinney JD, Oatley SJ, Blake CCF. Structurally specific binding of halogenated biphenyls to thyroxine transport. J Med Chem 29:641–648 (1986).

36. Brouwer A. Inhibition of thyroid hormone transport in plasma of rats by polychlorinated biphenyls. In: Biological monitoring of exposure and the response at the subcellular level of toxic substances. Arch Toxicol Suppl 13:440–445 (1989).

37. Grey LE Jr, Osby LJ, Marshall R, Andrews J. Reproductive and thyroid effects of low-level polychlorinated biphenyl (Aroclor 1254) exposure. Fundam Appl Toxicol 20:288–294 (1993).

38. Morse D, Groen D, Veerman M, van Amerongen C, Koeter CM, Smits van Pooijoe A, Visser T, Koeman J, Brouwer A. Interference of polychlorinated biphenyls in hepatic and brain thyroid hormone metabolism in fetal and neonatal rats. Toxicol Appl Pharmacol 122:27–33 (1993).

39. Ness D, Schantz S, Moshtaghian J, Hansen L. Effects of prenatal exposure to specific PCB congeners on thyroid hormone concentrations and thyroid histology in the rat. Toxicol Lett 68:311–323 (1993).

40. Krishnan V, Safe S. Polychlorinated biphenyls (PCBs), dibenzo-p-dioxins (PCDDs), and dibenzoofurans (PCDFs) as antiestrogens in MCF-7 human breast cancer cells: quantitative structure-activity relationships. Toxicol Appl Pharmacol 120:55–61 (1993).

41. Jansen H, Cooke P, Porcelli J, Liu T-S, Hansen L. Estrogenic and antiestrogenic actions of PCBs in the female rat: in vivo and in vitro studies. Reprod Toxicol 7:237–248 (1993).

42. Korach K, Sarver P, Chae K, McLachlan J, McKinney JD. Estrogen receptor-binding activity of polychlorinated hydroxybiphenyl: conformationally restricted structural probes. Mol Pharmacol 33:120–126 (1988).